Devices/Safety Alert·FDA MedWatch Safety Alerts

Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers

HighPublished Jun 11, 2026· AI-analyzed Jun 11, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Abiomed issued a correction for certain Automated Impella Controller (AIC) units requiring hardware updates to mitigate risks of delayed or lost hemodynamic support.

Who it affects

This affects Abiomed, healthcare facilities utilizing Automated Impella Controllers, and clinical staff responsible for managing patients requiring mechanical circulatory support.

Why it matters

The need for hardware updates suggests a potential design or component vulnerability that could lead to device failure during critical care. From a regulatory perspective, this qualifies as a significant field correction. Failure to implement these updates could result in acute clinical risks and increased liability for healthcare providers and the manufacturer if support is interrupted.

Practical takeaway

QA and clinical engineering teams should identify all in-site Automated Impella Controllers and coordinate with the manufacturer to facilitate required hardware updates. Clinical teams must be briefed on the risks of hemodynamic support delays until updates are completed. Ensure all field correction activities are documented in accordance with 21 CFR 806.

FDA source material

Certain AIC units require hardware updates to address potential safety concerns that could lead to a delay or loss of hemodynamic support.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.